HAD-B1, a Korean herbal mixture, has exhibited therapeutic potential as the adjuvant therapy to EGFR-TKIs by enhancing treatment efficacy and attenuating drug resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.